Livia Ramos Goes

Dr. Livia Ramos Goes

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in Mucosal Immunology
Verified
Journal Article
Open access
AGAlexandre Girard
Alexandre Girard
SVSinmanus Vimonpatranon
Sinmanus Vimonpatranon
ACAmanda Chan
Amanda Chan
AJAndrew Jiang
Andrew Jiang
DHDa Wei Huang
Da Wei Huang
CCClaudia Cicala
Claudia Cicala
Resident memory T cells (TRMs) help control local immune homeostasis and contribute to tissue protective immune responses. The local cues that guide their differentiation and localization are poorly defined. We demonstrate that MAdCAM-1, a ligand for the gut homing receptor α4β7 integrin, in the presence of retinoic acid and TGF-β provide a costimulatory signal that induces blood CD8+ T cells to adopt a TRM -like phenotype. These cells express CD103 (integrin αE) and CD69, the two major TRM cell surface markers, along with CD101. They also express CCR5, CCR9 and α4β7, three receptors associated with gut homing. A subset also express E-cadherin, a ligand for αEβ7. Fluorescent lifetime imaging indicated an αEβ7 and E-cadherin cis interaction on the plasma membrane. This report advances our understanding of the signals that drive the differentiation of CD8+ T cells into TRMs and provides a means to expand these cells in vitro, thereby affording an avenue to generate more effective tissue specific immunotherapies.

26 June 2024 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
ÉOÉlida Mendes de Oliveira
Élida Mendes de Oliveira
CSCaroline Carvalho de Sá
Caroline Carvalho de Sá
JCJulia Botto de Barros Cordeiro
Julia Botto de Barros Cordeiro
LTLuiz Claudio Santos Thuler
Luiz Claudio Santos Thuler
MAMaria Eduarda Lanzillota Assumpção
Maria Eduarda Lanzillota Assumpção
LGLivia Ramos Goes
Livia Ramos Goes
Introduction: The fast SARS-CoV-2 spread and high mutation rates during viral replication led to virus diversification and the emergence of new variants. Genomic surveillance has been key to monitoring SARS-CoV-2 variants across the globe. Immune suppression, as observed in cancer patients, is a risk factor for SARS-CoV-2 infection and severe COVID-19. Objective: To report a two-year genomic surveillance of SARS-CoV-2 in cancer patients followed up at the Brazilian National Cancer Institute, Rio de Janeiro, Brazil. Method: Prospective observational study with 384 SARS-CoV-2+ swabs specimens collected and evaluated between October 2020 and September 2022. SARS-CoV-2 spike was analyzed by PCR and Sanger sequencing to determine the infecting variant. Results: Most of the patients had solid organ malignancies (298/384; 77.6%) and 16.1% (62/384) had metastatic disease. Severe COVID-19 cases accounted for 29.4% (113/384) and 27.1% (104/384) of deaths registered. The most common SARS-CoV-2 infecting variants were Gamma (n=137) and Omicron (BA.1) (n=73). The variant distribution overtime was similar to what has been reported for the general population of Brazil in the same period. When patients’ cancer topographies were analyzed, it was found that Gamma infected patients with breast (47/137; 34.3%) and cervical (11/137; 8%) cancer were more frequent than other variants, while Omicron predominated among rectum (10/122; 8.2%) and prostate (8/122; 6.6%) cancer compared to other variants. Conclusion: Genomic surveillance is an important tool for identifying and evaluating the impact of SARS-CoV-2 variants, and should continue especially in immunosuppressed populations.

1 January 2025 in Ciência Rural
Verified
Journal Article
Open access
LLLeandro Ferreira Lopes Landeira
Leandro Ferreira Lopes Landeira
JPJuliana Aparecida Souza Paz
Juliana Aparecida Souza Paz
RCRaissa Mirella dos Santos Cunha da Costa
Raissa Mirella dos Santos Cunha da Costa
LGLivia Ramos Goes
Livia Ramos Goes
JSJuliana D. Siqueira
Juliana D. Siqueira
DNDirlei Nico
Dirlei Nico
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported in humans and various wild and domestic animals. The potential for SARS-CoV-2 transmission has been demonstrated in animal models. This study focused on the prevalence of SARS-CoV-2 RNA in domestic dogs and cats in São João de Meriti, Rio de Janeiro, Brazil.This study investigated the potential for domestic dogs and cats to be infected with SARS-CoV-2. Rectal swabs were collected from dogs and cats during routine veterinary visits between December 2020 and June 2021. Viral RNA was detected by real-time PCR, and Sanger sequencing was used to access the viral genome. A total of 650 samples were analyzed, with 48 (7.4%) testing positive for SARS-CoV-2. The positivite rate was 7.7% in dogs and 8.3% in cats. Fourteen animals exhibited clinical signs resembling COVID-19, the most prevalent being lack of appetite, vomiting, and diarrhea. The highest number of positive cases was observed in January 2021. One sample was successfully sequenced and identified as the Gamma (P.1) lineage. To the author’s knowledge, this is the largest Brazilian survey of SARS-CoV-2 in animals. It suggested that dogs and cats might be without clinical signs or present with mild clinical signs. There is no evidence that dogs and cats can spread SARS-CoV-2 back to humans.

21 March 2026 in Viruses
Verified
Journal Article
Open access
PDF file
BABrunna Alves
Brunna Alves
FMFilipe Moreira
Filipe Moreira
MGMarianne M. Garrido
Marianne M. Garrido
PSPedro Santos
Pedro Santos
ÉOÉlida Mendes de Oliveira
Élida Mendes de Oliveira
MSMarcelo Soares
Marcelo Soares
Based on the follow-up of patients who recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, several reports of people who re-tested positive have been described. This may result from viral reactivation, true reinfection, superinfection, or an initial infection by more than one virus (multiple infection). These scenarios can only be correctly distinguished through viral quasispecies analysis. Herein, 26 cancer patients under extended follow-up for SARS-CoV-2 infection were submitted to multiple longitudinal analyses through nucleic acid isolation, PCR amplification and high-throughput sequencing. SARS-CoV-2 classification and the definition of cases as persistent or repeated infections were based on phylogenetic reconstruction. Supported by their viral complete genomes and intrahost quasispecies over time, the different scenarios were identified. Nine confirmed and 12 plausible persistence cases were identified. Virus evolution dynamics in the intrahost population from patients with persistent infection was shown for the first time. Regarding reinfection, three confirmed and two plausible cases were identified, including one case of multiple infection. Altogether, this is the first study that analyzes the plethora of SARS-CoV-2 within-host minor variants and describes reinfections, multiple infections and viral evolution across time in cancer patients, contributing to the understanding of SARS-CoV-2’s within-host population dynamics in the natural history of COVID-19.